Harbour offshoot licenses hormone disorder antibody in $395 million deal

27 February 2025

HBM Alpha Therapeutics has signed a collaboration and licensing agreement, granting an unnamed business partner exclusive rights outside China to develop and commercialize its antibody therapy for hormone-related disorders.

The deal, announced Tuesday, could be worth up to $395 million in upfront and milestone payments, along with tiered royalties on future sales.

The therapy, HAT001, also known as HBM9013, is an antibody designed to neutralize corticotropin-releasing hormone (CRH), a key regulator of adrenal hormone production. It is being developed for conditions such as congenital adrenal hyperplasia (CAH), a rare genetic disorder caused by enzyme mutations that disrupt hormone synthesis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK